載入中
Oncolytics Biotech Inc., a clinical-stage biopharmaceutical company, engages in the research, development, and commercialization of oncology treatments. The company develops pelareorep, an intravenously delivered immunotherapeutic agent for the treatment of hormone receptor-positive / human epidermal growth factor 2-negative advanced and metastatic breast cancer, metastatic pancreatic ductal adenocarcinoma, and anal cancer. It has an agreement with Roche Holding AG to supply its immune checkpoint inhibitors, atezolizumab, for use in its ongoing sponsored studies. Oncolytics Biotech Inc. was incorporated in 1998 and is headquartered in Calgary, Canada.
一般交易時段
US$0.4645
−US$0.0088 · -1.86%
盤中時間採用ET。市場資料可能有所延遲。
Oncolytics Biotech Inc., a clinical-stage biopharmaceutical company, engages in the research, development, and commercialization of oncology treatments. The company develops pelareorep, an intravenously delivered immunotherapeutic agent for the treatment of hormone receptor-positive / human epidermal growth factor 2-negative advanced and metastatic breast cancer, metastatic pancreatic ductal adenocarcinoma, and anal cancer. It has an agreement with Roche Holding AG to supply its immune checkpoint inhibitors, atezolizumab, for use in its ongoing sponsored studies. Oncolytics Biotech Inc. was incorporated in 1998 and is headquartered in Calgary, Canada.
日內區間
目前US$0.4645
52週區間
目前US$0.4645
盤中時間採用ET。市場資料可能有所延遲。
Oncolytics Biotech Inc., a clinical-stage biopharmaceutical company, engages in the research, development, and commercialization of oncology treatments. The company develops pelareorep, an intravenously delivered immunotherapeutic agent for the treatment of hormone receptor-positive / human epidermal growth factor 2-negative advanced and metastatic breast cancer, metastatic pancreatic ductal adenocarcinoma, and anal cancer. It has an agreement with Roche Holding AG to supply its immune checkpoint inhibitors, atezolizumab, for use in its ongoing sponsored studies. Oncolytics Biotech Inc. was incorporated in 1998 and is headquartered in Calgary, Canada.
日內區間
目前US$0.4645
52週區間
目前US$0.4645
營業利益
淨利
| 項目（CAD） | 2025會計年度 | 2024會計年度 | 2023會計年度 | 2022會計年度 | 2021會計年度 |
|---|---|---|---|---|---|
| 研究與開發 | 1331.4萬 CAD | 1544.3萬 CAD | 1334.92萬 CAD | 1137.05萬 CAD | 1292萬 CAD |
| 銷售、一般及管理費用 | 1541.1萬 CAD | 1009.9萬 CAD | 1181.89萬 CAD | 817.86萬 CAD | 1286.3萬 CAD |
| 營業費用 | 2872.5萬 CAD | 2554.2萬 CAD | 2547.19萬 CAD | 1983.79萬 CAD | 2623.49萬 CAD |
| 利息收入 | 52.96萬 CAD | 119.9萬 CAD | 132.6萬 CAD | 52.8萬 CAD | — |
| 折舊和攤銷 | 7萬 CAD | 8.7萬 CAD | 30.38萬 CAD | 28.88萬 CAD | 45.2萬 CAD |
| 營業利益 | −2872.5萬 CAD | −2554.2萬 CAD | −2547.19萬 CAD | −1983.79萬 CAD | −2623.49萬 CAD |
| 淨利 | −2875.9萬 CAD | −2279.4萬 CAD | −2091.96萬 CAD | −1829.87萬 CAD | −2630.4萬 CAD |
公司資料更新於 2026年10月13日。
第三方分析師預期可能變動，並非 GoAI 建議。
| 行動 | 生效日期 | 詳情 | 記錄日期 | 付款日期 |
|---|---|---|---|---|
股票分割 | 2018年5月25日 | 2:19 | — | — |
已生效 2018年5月25日
2:19
報告持有此股票曝險的交易所交易基金。
AI 生成內容及延遲市場資料僅供資訊與教育用途，不構成投資建議。
